BoneSupport makes CERAMENT, a injectable bone-void filler that hardens in situ to treat fractures and bone defects, with CERAMENT G (gentamicin-loaded) positioned as a combined filler and local antibiotic for infected or high-risk surgical sites. The moat is a single-product franchise with a 92.0% gross margin, a structural tailwind from orthopedic and trauma procedures that favour a fast, off-the-shelf, non-autograft solution, and a clinical evidence base that hospital procurement teams tend to stick with. The near-term driver is adoption of CERAMENT G across more hospitals and wider reimbursement and guideline acceptance for infection-prevention use, which is where the company's revenue growth of 25.1% is coming from. It screens as interesting now because the growth rate and 23.9% operating margin are rare for a company of this size, but the stock trades at 99.6 times trailing earnings and 73.2 times forward earnings, so the entire thesis rests on sustaining high-teens-plus growth for years; that is the question worth testing in a deeper look.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | kr 285 | first publication | kr 320 |
Answered from Bonesupport Holding AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| BONEX.ST Bonesupport Holding AB (publ) | kr 332.60 | - | - | 81.5x | 24.5% | 88 | 72 |
| ALIF-B.ST AddLife AB (publ) | kr 180.70 | kr 133 | 36% above | 35.0x | 11.5% | 54 | 54 |
| ICUI ICU Medical Inc. Common Stock | $168.33 | $111 | 52% above | 134.7x | 1.4% | 43 | 50 |
| 1SXP.DE SCHOTT Pharma AG & Co. KGaA | €25.55 | €17 | 49% above | 28.6x | 14.7% | 69 | 61 |
| ANN.AX Ansell Limited | A$45.76 | A$40 | 15% above | 21.6x | 10.5% | 67 | 75 |
| MMED MiniMed Group Inc. Common Stock | $18.29 | - | - | - | -8.7% | 43 | 54 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $19.50 | $12 | 57% above | 34.2x | 9.1% | 63 | 47 |
Where BONEX.ST ranks against its sector peers on each metric.